Skip to main content
9 search results for:

Teplizumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 23-10-2023 | Type 1 diabetes | News | Article

    Teplizumab may PROTECT β-cell function in youth with newly diagnosed type 1 diabetes

    Early treatment with the anti-CD3 monoclonal antibody teplizumab may help to preserve β-cell function in children and adolescents with newly diagnosed type 1 diabetes, results of the phase 3 PROTECT study show.

  2. 12-09-2023 | Type 1 diabetes | News | Article

    Preservation of β-cell function with teplizumab in type 1 diabetes confirmed

    Teplizumab consistently preserves the function of β-cells in people with type 1 diabetes as measured by higher C-peptide levels at 1 and 2 years post-treatment.

  3. 18-11-2022 | Teplizumab | News | Article
    approvalsWatch

    FDA clearance for teplizumab to slow type 1 diabetes onset

    Teplizumab is an anti-CD3 antibody, which modifies CD8+ T lymphocytes.

  4. 05-03-2021 | Teplizumab | News | Article

    Teplizumab offers extended preservation of beta-cell function

    Prolonged follow-up of high-risk people treated with teplizumab to prevent progression to type 1 diabetes shows a lasting beneficial effect on beta-cell function, say researchers.

  5. 09-06-2019 | Diabetes prevention | ADA 2019 | Article

    Teplizumab delays onset of overt type 1 diabetes

    Phase II findings show that the immunotherapy teplizumab significantly prolongs the time until people at very high risk for developing type 1 diabetes are diagnosed with the condition.

  6. 14-06-2019 | Diabetes prevention | News | Article

    Teplizumab, low-dose ATG hold greatest type 1 diabetes immunotherapy promise

    Of the immunotherapies tested to date, teplizumab and low-dose antithymocyte globulin are the most promising for slowing the decline in C-peptide in people with newly diagnosed type 1 diabetes, researchers report.

  7. 20-05-2022 | Immunotherapy | Hot topic review | Article

    How far has immunotherapy for type 1 diabetes progressed?

    But at phase 3 neither otelixizumab, in the DEFEND trial [16], nor teplizumab, in the Protégé study [17], significantly slowed C-peptide decline.

  8. 26-01-2023 | Screening | News | Article

    Age 10 years is optimal type 1 diabetes screening point for adolescents

    They add that the recent US approval of teplizumab  for slowing the onset of clinical type 1 diabetes in high-risk individuals may increase the perceived value of screening programs and spur their initiation to facilitate timely intervention with this medication. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2023 Springer Healthcare Ltd, part of the Springer Nature Group Lancet Child Adolesc Health 2023; doi:10.1016/S2352-4642(22)00350-9 Lancet Child Adolesc Health 2023; doi:10.1016/S2352-4642(23)00001-9

  9. 05-02-2020 | Children | News | Article

    One in 300 young children may have presymptomatic type 1 diabetes

    The investigators also suggest that primary care screening “could rapidly disseminate access to therapies” for children with stage 2 diabetes who may benefit from a single 14-day course of teplizumab to delay progression to stage 3. medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature group JAMA 2020; 323 : 339–351

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.